Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Untying the gordion knot of targeting MET in cancer.

Raghav K, Bailey AM, Loree JM, Kopetz S, Holla V, Yap TA, Wang F, Chen K, Salgia R, Hong D.

Cancer Treat Rev. 2018 May;66:95-103. doi: 10.1016/j.ctrv.2018.04.008. Epub 2018 Apr 26. Review.

PMID:
29730462
2.

Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer.

Loree JM, Bailey AM, Johnson AM, Yu Y, Wu W, Bristow CA, Davis JS, Shaw KR, Broaddus R, Banks KC, Lanman RB, Meric-Bernstam F, Overman MJ, Kopetz S, Raghav K.

J Natl Cancer Inst. 2018 Apr 27. doi: 10.1093/jnci/djy067. [Epub ahead of print]

PMID:
29718453
3.

Correction to: Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer.

Lam M, Loree JM, Pereira AAL, Chun YS, Kopetz S.

Curr Treat Options Oncol. 2018 Apr 23;19(5):25. doi: 10.1007/s11864-018-0537-x.

PMID:
29687230
4.

Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer.

Lam M, Loree JM, Lima AAP, Chun YS, Kopetz S.

Curr Treat Options Oncol. 2018 Feb 27;19(2):11. doi: 10.1007/s11864-018-0524-2. Review. Erratum in: Curr Treat Options Oncol. 2018 Apr 23;19(5):25.

PMID:
29488033
5.

Survival Impact of CAPOX Versus FOLFOX in the Adjuvant Treatment of Stage III Colon Cancer.

Loree JM, Sha A, Soleimani M, Kennecke HF, Ho MY, Cheung WY, Mulder KE, Abadi S, Spratlin JL, Gill S.

Clin Colorectal Cancer. 2018 Jun;17(2):156-163. doi: 10.1016/j.clcc.2018.01.010. Epub 2018 Feb 7.

PMID:
29486916
6.

Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer.

Strickler JH, Loree JM, Ahronian LG, Parikh AR, Niedzwiecki D, Pereira AAL, McKinney M, Korn WM, Atreya CE, Banks KC, Nagy RJ, Meric-Bernstam F, Lanman RB, Talasaz A, Tsigelny IF, Corcoran RB, Kopetz S.

Cancer Discov. 2018 Feb;8(2):164-173. doi: 10.1158/2159-8290.CD-17-1009. Epub 2017 Dec 1.

PMID:
29196463
7.

Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes.

Loree JM, Pereira AAL, Lam M, Willauer AN, Raghav K, Dasari A, Morris VK, Advani S, Menter DG, Eng C, Shaw K, Broaddus R, Routbort MJ, Liu Y, Morris JS, Luthra R, Meric-Bernstam F, Overman MJ, Maru D, Kopetz S.

Clin Cancer Res. 2018 Mar 1;24(5):1062-1072. doi: 10.1158/1078-0432.CCR-17-2484. Epub 2017 Nov 27.

PMID:
29180604
8.

Real-World Effect of Maintenance and Intermittent Chemotherapy on Survival in Metastatic Colorectal Cancer.

Loree JM, Tan SK, Lafond LM, Speers CH, Kennecke HF, Cheung WY.

Clin Colorectal Cancer. 2018 Mar;17(1):65-72. doi: 10.1016/j.clcc.2017.10.011. Epub 2017 Oct 23.

PMID:
29153430
9.

Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing.

Wong HL, Yang KC, Shen Y, Zhao EY, Loree JM, Kennecke HF, Kalloger SE, Karasinska JM, Lim HJ, Mungall AJ, Feng X, Davies JM, Schrader K, Zhou C, Karsan A, Jones SJM, Laskin J, Marra MA, Schaeffer DF, Gorski SM, Renouf DJ.

Cold Spring Harb Mol Case Stud. 2018 Feb 1;4(1). pii: a002329. doi: 10.1101/mcs.a002329. Print 2018 Feb.

10.

Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature.

Korphaisarn K, Loree JM, Nguyen V, Coulson R, Holla V, Litzenburger BC, Chen K, Mills GB, Maru DM, Meric-Bernstan F, Shaw KRM, Kopetz S.

Oncotarget. 2017 Jun 3;8(34):57882-57888. doi: 10.18632/oncotarget.18357. eCollection 2017 Aug 22.

11.

Recent developments in the treatment of metastatic colorectal cancer.

Loree JM, Kopetz S.

Ther Adv Med Oncol. 2017 Aug;9(8):551-564. doi: 10.1177/1758834017714997. Epub 2017 Jun 29. Review.

12.

Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases.

Chun YS, Passot G, Yamashita S, Nusrat M, Katsonis P, Loree JM, Conrad C, Tzeng CD, Xiao L, Aloia TA, Eng C, Kopetz SE, Lichtarge O, Vauthey JN.

Ann Surg. 2017 Aug 1. doi: 10.1097/SLA.0000000000002450. [Epub ahead of print]

PMID:
28767562
13.

Platelet "first responders" in wound response, cancer, and metastasis.

Menter DG, Kopetz S, Hawk E, Sood AK, Loree JM, Gresele P, Honn KV.

Cancer Metastasis Rev. 2017 Jun;36(2):199-213. doi: 10.1007/s10555-017-9682-0. Review.

14.

Why a One Size Fits All Approach to RAS Might Not Fit Colorectal Cancer.

Loree JM, Kopetz S.

J Natl Compr Canc Netw. 2017 Apr;15(4):545-547. No abstract available.

PMID:
28404763
15.

Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer.

Thierry AR, Pastor B, Jiang ZQ, Katsiampoura AD, Parseghian C, Loree JM, Overman MJ, Sanchez C, Messaoudi SE, Ychou M, Kopetz S.

Clin Cancer Res. 2017 Aug 15;23(16):4578-4591. doi: 10.1158/1078-0432.CCR-17-0232. Epub 2017 Apr 11.

PMID:
28400427
16.

Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie.

Loree JM, Kopetz S, Raghav KP.

J Gastrointest Oncol. 2017 Feb;8(1):199-212. doi: 10.21037/jgo.2017.01.01. Review.

17.

Impact of Postoperative Adjuvant Chemotherapy Following Long-course Chemoradiotherapy in Stage II Rectal Cancer.

Loree JM, Kennecke HF, Lee-Ying RM, Goodwin RA, Powell ED, Tang PA, Price Hiller JA, Vickers MM, Cheung WY.

Am J Clin Oncol. 2018 Jul;41(7):643-648. doi: 10.1097/COC.0000000000000342.

PMID:
27819876
18.

Impact of Travel Distance and Urban-Rural Status on the Multidisciplinary Management of Rectal Cancer.

Loree JM, Javaheri KR, Lefresne SV, Speers CH, Ruan JY, Chang JT, Brown CJ, Kennecke HF, Olson RA, Cheung WY.

J Rural Health. 2017 Sep;33(4):393-401. doi: 10.1111/jrh.12219. Epub 2016 Oct 7.

PMID:
27717002
19.

Leukocytoclastic vasculitis following lenalidomide during the treatment of follicular lymphoma.

Loree JM, Cai E, Sheffield BS, Dutz JP, Villa D, Shepherd LE, Connors JM, Sehn LH, Savage KJ.

Leuk Lymphoma. 2017 Mar;58(3):711-714. doi: 10.1080/10428194.2016.1204657. Epub 2016 Aug 25. No abstract available.

PMID:
27557805
20.

Optimizing adjuvant therapy and survivorship care of stage III colon cancer.

Loree JM, Cheung WY.

Future Oncol. 2016 Sep;12(17):2021-35. doi: 10.2217/fon-2016-0109. Epub 2016 Jun 15. Review.

PMID:
27301775
21.

Effect of Adjuvant Chemotherapy on Stage II Rectal Cancer Outcomes After Preoperative Short-Course Radiotherapy.

Loree JM, Kennecke HF, Renouf DJ, Lim HJ, Vickers MM, Speers CH, Cheung WY.

Clin Colorectal Cancer. 2016 Dec;15(4):352-359.e1. doi: 10.1016/j.clcc.2016.04.003. Epub 2016 May 7.

PMID:
27265355
22.

Case Report of Cirrhosis following Yttrium-90 Radioembolization for Pancreatic Neuroendocrine Liver Metastases.

Loree JM, Hiruki T, Kennecke HF.

Case Rep Oncol. 2016 Jan 30;9(1):76-82. doi: 10.1159/000443985. eCollection 2016 Jan-Apr.

23.

CAPOX associated with toxicities of higher grade but improved disease-free survival when compared with FOLFOX in the adjuvant treatment of stage III colon cancer.

Loree JM, Mulder KE, Ghosh S, Spratlin JL.

Clin Colorectal Cancer. 2014 Sep;13(3):172-7. doi: 10.1016/j.clcc.2014.01.001. Epub 2014 Feb 6.

PMID:
24630275
24.

Retrospective comparison of CAPOX and FOLFOX dose intensity, toxicity, and clinical outcomes in the treatment of metastatic colon cancer.

Loree JM, Mulder KE, Ghosh S, Spratlin JL.

J Gastrointest Cancer. 2014 Jun;45(2):154-60. doi: 10.1007/s12029-013-9574-7.

PMID:
24408272

Supplemental Content

Loading ...
Support Center